IRNF App vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Apple
VS
by Tempus AI, Inc.

AI Verdict

These tools are adjacent rather than direct competitors, as they address different aspects of Atrial Fibrillation (AFib) management. The IRNF App is a consumer-facing mobile feature for personal monitoring of irregular heart rhythms suggestive of AFib, while Tempus ECG-AF is a clinical AI algorithm designed for healthcare facilities to predict the risk of new-onset AFib in older patients based on 12-lead ECGs.

Choose IRNF App if…

Choose the IRNF App if you are an individual seeking a convenient, over-the-counter solution for continuous, passive monitoring of irregular heart rhythms suggestive of Atrial Fibrillation (AFib) through your Apple Watch. This tool is ideal for proactive self-monitoring and receiving notifications directly on your mobile device, integrating seamlessly with your personal health data.

View IRNF App →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if you are a healthcare provider looking to clinically assess patients aged 65 or older for their risk of developing new-onset Atrial Fibrillation within the next 12 months. This AI-based algorithm integrates into healthcare facility systems to analyze 12-lead ECGs, providing valuable risk stratification to guide further diagnostic workup and preventative care within a medical setting.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature IRNF App Tempus ECG-AF
Pricing Free Contact vendor
Deployment Mobile (iOS, watchOS) Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available No AI-estimated Yes AI-estimated
FDA Status 1 AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

IRNF App

Tool A, the IRNF App, is designed for direct consumer use on personal mobile devices like the Apple Watch and iPhone, offering intuitive integration with Apple Health and educational materials. Tool B, Tempus ECG-AF, is integrated into healthcare facility systems, requiring professional operation within a clinical workflow. Therefore, Tool A is significantly more accessible and user-friendly for the general public.

Clinical Value

Tempus ECG-AF

Tool A provides real-time detection of irregular rhythms suggestive of AFib, empowering individuals to seek timely medical attention. Tool B offers a predictive risk assessment for new-onset AFib within 12 months for a high-risk population (65+), enabling proactive clinical management and earlier intervention. Tool B's ability to predict future risk using a standard diagnostic allows for more impactful preventative strategies within a healthcare system.

Pricing & Value

IRNF App

Tool A is a free feature included with compatible Apple Watch and iPhone models, offering immense value at no additional cost to the end-user. Tool B is a paid service with specific CMS reimbursement available, representing a cost to the healthcare provider or system. Tool A's free availability provides unparalleled value and accessibility.

Enterprise Readiness

Tempus ECG-AF

Tool A is a consumer mobile application with no stated Business Associate Agreement (BAA) or enterprise integration features. Tool B explicitly states HIPAA compliance and a BAA, and is designed for integration into healthcare facility systems. Tool B is purpose-built for enterprise deployment within healthcare, adhering to critical compliance standards.

Innovation

Tie

Tool A innovates by democratizing FDA-cleared AFib detection through a widely adopted consumer wearable, making health monitoring accessible to a broad population. Tool B innovates by applying AI to standard 12-lead ECGs to predict future AFib risk in a specific demographic, enabling novel proactive clinical strategies. Both represent significant innovation in their respective domains.

Support & Docs

IRNF App

Tool A, as an Apple product, benefits from Apple's extensive user support infrastructure, readily available online documentation, and in-app educational materials. Tool B, as an enterprise solution, would have vendor-specific support channels for healthcare facilities, but public documentation and direct user support details are not specified. Tool A likely offers superior and more accessible support for its target users.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature IRNF App Tempus ECG-AF
Name IRNF App Tempus ECG-AF
Company Apple Tempus AI, Inc.
Target Population/Use Case Detects irregular heart rhythms suggestive of Atrial Fibrillation (AFib) and notifies users; Over-the-counter (OTC) use. Identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.
Input Data Pulse rate data analysis using Apple Watch PPG sensor 12-lead ECG recordings (compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems)
Detection Mechanism Irregular heart rhythm detection; Utilizes machine learning for rhythm classification. AI-based algorithm that analyzes 12-lead ECG recordings.
Specialties Cardiology, Internal Medicine Cardiology, Geriatrics, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring IRNF App and Tempus ECG-AF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tool A, the Apple Irregular Rhythm Notification Feature, is a patient-driven, passive monitoring tool where data is accessed via the Apple Health app, suitable for general population screening for irregular heart rhythms suggestive of AFib. Tool B, Tempus ECG-AF, integrates into existing 12-lead ECG platforms and EHRs, providing AI-driven risk stratification for new-onset AF in specific older patient groups within a healthcare facility's workflow.
Tool A primarily integrates with the Apple Health app, relying on patients to share their data with physicians, and displays a history of AFib notifications. Tool B is designed for integration into healthcare facility systems and EHRs, allowing for advanced AI deployment and insights within clinical workflows and filtering eligible patients using EHR data.
Tool A detects irregular heart rhythms suggestive of AFib using a PPG sensor for real-time notification, with studies showing varying sensitivity (e.g., 21.4% in one study) but high specificity (e.g., 100%). Tool B analyzes 12-lead ECGs to identify patients aged 65 or older at increased risk of developing new-onset AF within 12 months, demonstrating a sensitivity of 31% and a specificity of 92% for classifying patients who developed AF within one year.
Tool A is broadly applicable for individuals aged 22 years and over interested in pre-screening for irregular rhythms suggestive of AFib, fitting general cardiology and internal medicine practices. Tool B is specifically intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, making it suitable for cardiology, geriatrics, and internal medicine in a clinical setting for risk prediction.
Tool A has a minimal learning curve for physicians, as it is patient-initiated with data presented via the Apple Health app, and users complete onboarding materials. Tool B requires understanding the AI algorithm's output and its integration into existing clinical systems, with Tempus emphasizing integration into clinicians' existing workflows without adding complexity.
Tool A provides a history of AFib notifications within the Apple Health app, allowing users to view when irregular tachograms contributed to a notification. Tool B, as an integrated software solution within healthcare facility systems, would likely leverage existing audit functionalities for tracking analyses and physician interactions, though specific audit trail features are not detailed in the provided information.

Backers

Who funded each tool's parent company.

IRNF App

Tempus ECG-AF

AI Tool Finder
AI-powered search. Results may not be comprehensive.